Oxford BioDynamics Plc

Oxford BioDynamics has signed its first commercial pharmaceutical agreement for EpiSwitch Orion, with Johnson & Johnson using the platform in inflammatory bowel disease biomarker research. The contract provides an important commercial reference for the AIM-listed genomics company, but undisclosed economics and a history of operating losses mean customer validation must still be converted into meaningful revenue.